(Q45019665)

8 December 2017

title

New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment (English)

1 reference

8 December 2017

Ping-I Hsu

1

1 reference

8 December 2017

publication date

1 April 2012

1 reference

Journal of Gastroenterology and Hepatology

8 December 2017

published in

1 reference

8 December 2017

volume

27

1 reference

8 December 2017

issue

4

1 reference

8 December 2017

page(s)

654-661

1 reference

Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events

8 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Study for determination of the optimal cessation period of therapy with anti-platelet agents prior to invasive endoscopic procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Antiplatelet drug discontinuation is a risk factor for ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Bleeding peptic ulcer--risk factors for rebleeding and sequential changes in endoscopic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

NSAID-induced gastrointestinal and cardiovascular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Should prophylactic low-dose aspirin therapy be continued in peptic ulcer bleeding?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk -- a single-blind, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Proton pump inhibitor and clopidogrel interaction: fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Management of patients with high gastrointestinal risk on antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Drug-drug interaction between clopidogrel and the proton pump inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Pantoprazole: a new proton pump inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

Clopidogrel with or without omeprazole in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07085.X

10.1111/J.1440-1746.2012.07085.X

21 January 2018

Identifiers

DOI

1 reference

8 December 2017

1 reference